Equibles does not estimate personal net worth.
Get an email with a short summary when Recursion Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get RXRX alertsNajat Khan is recorded as CEO at Recursion Pharmaceuticals, Inc. (RXRX). The newest filing on record that lists Najat Khan as CEO at Recursion Pharmaceuticals, Inc. (RXRX) is dated April 30, 2026. The proxy statement of Recursion Pharmaceuticals, Inc. reports total compensation of $5,349,065 for Najat Khan in fiscal 2025, including a base salary of $600,000. Disclosed compensation is on record for 2 fiscal years. Najat Khan has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Recursion Pharmaceuticals, Inc. on September 15, 2026. Recursion Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Recursion Pharmaceuticals, Inc. includes Christopher C. Gibson (CEO and Board Member), Najat Khan, Ph.D. (CEO and Board Member), Christopher Gibson, Ph.D. (Chairman) and 7 others.
“I think all of the above are, of course, important to take a drug and actually commercialize and ensure this access to patients. For the stage of the company that recursion is, FDA, regulatory, you know, guidance, et cetera, is critically important. and we have a very productive relationship with regulators.”
“Since stepping into this role, I've been focused on one question: how do we harness the full power of AI to urgently and consistently create better medicines for patients?”
“I want to start by briefly framing where recursion is today in its journey and evolution.”
“It is truly an honor to take on the role of CEO and President of Recursion. I want to express my gratitude to you, the Board, and our amazing team for their trust and support.”
Start not stated–present
Last confirmed April 30, 2026
2024-01-01–2025-04-28
Last confirmed by a filing; no departure on record
Proxy statement
Start not stated–2025-04-28
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CEO
2024-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Recursion Pharmaceuticals, Inc. (RXRX) | current Chief Executive Officer and President | $600,000 | $5,349,065 |
| 2024 | Recursion Pharmaceuticals, Inc. (RXRX) | Chief R&D and Chief Commercial Officer | $285,000 | $9,194,805 |
